Metformin and gastric sleeve surgery is an important consideration for anyone with type 2 diabetes undergoing sleeve gastrectomy in the UK. Gastric sleeve surgery can dramatically alter blood glucose levels — sometimes within days of the procedure — meaning that diabetes medications, including metformin, often require prompt review and adjustment. Understanding how the surgery affects metformin's safety, absorption, and dosing is essential for both patients and clinicians. This article outlines what to expect before and after surgery, relevant NICE and NHS guidance, and the long-term monitoring needed to manage diabetes safely following sleeve gastrectomy.

How Gastric Sleeve Surgery Affects Type 2 Diabetes Management

Gastric sleeve surgery can lead to rapid improvement or remission of type 2 diabetes, often within days of the procedure, through mechanisms including reduced caloric intake, altered gut hormone secretion, and improved insulin sensitivity.

Gastric sleeve surgery, formally known as sleeve gastrectomy, is one of the most commonly performed bariatric procedures in the UK. It involves removing approximately 75–80% of the stomach, leaving a narrow, sleeve-shaped pouch. Beyond its role in weight reduction, the procedure can have a profound and often rapid effect on type 2 diabetes — sometimes before significant weight loss has even occurred.

The mechanisms behind this metabolic improvement are not fully understood, but several factors are thought to contribute:

• Reduced caloric intake leading to improved insulin sensitivity

• Changes in gut hormone secretion, including possible increases in GLP-1 (glucagon-like peptide-1), which may enhance insulin release

• Altered bile acid metabolism, which may influence glucose regulation

• Reduced hepatic fat, improving liver insulin sensitivity

It is important to note that the evidence for these mechanisms is stronger for Roux-en-Y gastric bypass than for sleeve gastrectomy; the above explanations remain plausible hypotheses for the sleeve procedure.

For many patients, blood glucose levels begin to normalise within days to weeks of surgery, ahead of substantial weight loss. Published data suggest that a meaningful proportion of people with type 2 diabetes experience significant improvement or complete remission following sleeve gastrectomy, though rates are generally lower than those reported after gastric bypass and vary depending on follow-up duration and how remission is defined. Remission is typically defined as an HbA1c below 48 mmol/mol sustained for at least three months without glucose-lowering therapy.

Outcomes vary depending on the duration of diabetes, baseline HbA1c, and degree of residual beta-cell function. Patients with a shorter history of diabetes and better-preserved pancreatic function tend to achieve the most durable remission. Nonetheless, all patients with type 2 diabetes undergoing gastric sleeve surgery should expect their diabetes management plan to change significantly in the post-operative period, and should not adjust their medicines independently — any changes must be made with their GP, diabetologist, or specialist bariatric team.

Metformin Use Before and After Gastric Sleeve Surgery

Metformin must be stopped at the time of surgery and restarted no earlier than 48 hours post-operatively once renal function is stable; post-operative doses are often reduced or discontinued if diabetes remission is achieved.

Metformin is the first-line oral medication for type 2 diabetes in the UK, recommended by NICE (NG28) and NHS guidelines. It works primarily by reducing hepatic glucose production (gluconeogenesis) and improving peripheral insulin sensitivity. When used alone, metformin does not cause hypoglycaemia. Its well-established safety profile and low cost make it a cornerstone of diabetes management.

Before surgery, the UK metformin Summary of Product Characteristics (SmPC) advises that metformin should be stopped at the time of surgery performed under general, spinal, or epidural anaesthesia, and restarted no earlier than 48 hours afterwards, once renal function has been confirmed as stable. Local protocols from the Centre for Perioperative Care (CPOC) and the Joint British Diabetes Societies (JBDS) may provide additional or more specific guidance, and patients must follow the pre-operative instructions given by their own surgical and anaesthetic team.

After surgery, the situation changes considerably. As blood glucose levels often improve rapidly post-operatively, continuing metformin at the same dose may no longer be appropriate. The post-operative period typically involves:

• A liquid or puréed diet for several weeks, which itself reduces carbohydrate load and blood glucose

• Rapid changes in gut physiology that alter drug absorption and tolerability

• Frequent reassessment of HbA1c and fasting glucose to guide medication decisions

For patients who do continue metformin after gastric sleeve surgery, the dose is often reduced. Some patients may be able to discontinue it entirely if diabetes remission is achieved and sustained. Metformin should be reviewed at each post-operative follow-up appointment.

Renal function and dosing: Metformin is contraindicated when eGFR falls below 30 mL/min/1.73m². When eGFR is between 30 and 44 mL/min/1.73m², the dose should be reviewed and renal function monitored more frequently, as the risk of lactic acidosis increases. eGFR can fluctuate post-operatively due to changes in hydration and body composition, so regular monitoring is important.

Sick-day rules: Metformin should be temporarily withheld during episodes of vomiting, diarrhoea, dehydration, severe infection, or any condition causing hypoxia or haemodynamic instability, as these increase the risk of lactic acidosis. It should also be stopped before administration of iodinated contrast media and not restarted until at least 48 hours afterwards, once renal function is confirmed as normal. Patients should follow NHS sick-day rules guidance and seek advice from their GP or pharmacist if unsure.

Any changes to metformin should be made in consultation with a GP, diabetologist, or specialist bariatric team — patients should not adjust or stop their medication independently.

Absorption Changes and Dosing Considerations Post-Surgery

Sleeve gastrectomy preserves the normal gastrointestinal pathway, so metformin absorption is less affected than after gastric bypass, but immediate-release formulations are preferred early post-operatively due to faster gastric emptying and tolerability concerns.

One of the key pharmacological considerations following gastric sleeve surgery is how the procedure affects drug absorption. Unlike gastric bypass (Roux-en-Y), which reroutes the digestive tract and significantly alters the absorptive surface of the gut, sleeve gastrectomy preserves the normal gastrointestinal pathway. The stomach is reduced in size, but the pylorus, small intestine, and large intestine remain intact and in their original anatomical positions.

This means that metformin absorption is generally less dramatically affected by sleeve gastrectomy than by bypass procedures. However, several practical changes can still influence how the drug behaves:

• Faster gastric emptying post-sleeve may alter the rate at which metformin reaches the small intestine, potentially affecting peak plasma concentrations

• Reduced stomach acid production (due to removal of acid-secreting cells) may theoretically influence the dissolution of standard tablets, though the direct clinical relevance for metformin specifically is limited

• Modified-release (MR) metformin formulations may have less predictable absorption in the early post-operative period; immediate-release (IR) formulations are generally preferred initially, as they offer more consistent pharmacokinetics

• Gastrointestinal side effects — nausea, bloating, and diarrhoea — are already common with metformin and may be exacerbated in the early post-operative period when the gut is adapting

If metformin is continued after gastric sleeve surgery, clinicians will typically prefer immediate-release tablets over modified-release or enteric-coated formulations in the early post-operative period. Modified-release tablets must not be crushed, as this destroys the controlled-release mechanism and may lead to dose-dumping. If swallowing tablets is difficult, a liquid or dispersible immediate-release preparation may be considered — patients should seek advice from their pharmacist or bariatric team before making any change to formulation.

Dose titration should be guided by tolerance and glycaemic response. The Specialist Pharmacy Service (SPS) and BOMSS (British Obesity and Metabolic Surgery Society) provide specific guidance on medicines management after bariatric surgery, which bariatric teams will follow. Patients should report persistent gastrointestinal symptoms to their GP or bariatric team, as these may indicate poor tolerability rather than a normal post-operative adjustment.

NICE and NHS Guidance on Diabetes Medicines After Bariatric Surgery

NICE (NG28, CG189) and NHS guidance recommend prompt medication review after bariatric surgery, with insulin and sulphonylureas reduced early to prevent hypoglycaemia and SGLT-2 inhibitors withheld until normal eating resumes due to DKA risk.

NICE guidance — including NG28 (Type 2 diabetes in adults: management) and CG189 (Obesity: identification, assessment and management) — acknowledges that bariatric surgery can lead to significant improvement or remission of type 2 diabetes and recommends that diabetes medications be reviewed promptly following surgery. The NHS also provides guidance through specialist bariatric and diabetes services, emphasising the importance of a structured, multidisciplinary approach to post-operative medication management.

Key principles from NICE, NHS, CPOC, and JBDS guidance include:

• Medication review at discharge and at each post-operative follow-up appointment, with adjustments based on blood glucose monitoring and HbA1c results

• Insulin and sulphonylureas (e.g., gliclazide) should be reduced or stopped early post-operatively to avoid hypoglycaemia, as these carry a direct risk of low blood sugar

• Metformin may be continued if tolerated and if glycaemic control requires it, but should be reviewed regularly — it is not automatically continued indefinitely. Standard contraindications (particularly renal function thresholds) continue to apply

• SGLT-2 inhibitors (e.g., dapagliflozin, empagliflozin) should be stopped before surgery — typically at least three days before the procedure (four days for ertugliflozin) — and withheld during the post-operative period while caloric intake remains low, due to the risk of euglycaemic diabetic ketoacidosis (DKA). They should only be restarted once the patient is eating normally, ketone levels are normal, and a specialist has confirmed it is safe to do so. The MHRA has issued Drug Safety Updates on this risk, and patients should be aware of DKA symptoms (nausea, vomiting, abdominal pain, breathlessness) and seek urgent medical attention if these occur

• GLP-1 receptor agonists (e.g., semaglutide, liraglutide) should be reviewed on an individual basis by the specialist team

Patients should ensure their renal function is monitored regularly post-operatively. Any patient unsure about which medications to continue after surgery should seek advice from their GP or specialist team before making any changes independently.

Still have questions? Message our pharmacists for free →

Suspected side effects from any medicine should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Monitoring Blood Sugar and Reviewing Medication Long-Term

Long-term monitoring after gastric sleeve surgery includes at least annual HbA1c testing, renal function checks, and vitamin B12 monitoring, as diabetes remission is not always permanent and metformin can reduce B12 absorption over time.

Long-term monitoring is essential for anyone with type 2 diabetes who has undergone gastric sleeve surgery. While many patients achieve remission — defined as an HbA1c below 48 mmol/mol sustained for at least three months without glucose-lowering therapy — this is not always permanent. Weight regain, changes in diet, or the natural progression of beta-cell decline can lead to the return of elevated blood glucose levels, sometimes months or years after surgery. Ongoing vigilance is therefore critical, and annual HbA1c testing is recommended even during periods of apparent remission.

Recommended monitoring schedule (in line with NHS, NICE, and BOMSS guidance) typically includes:

• Self-monitoring of blood glucose in the early post-operative weeks, particularly if on insulin or sulphonylureas

• HbA1c testing at 3 months, 6 months, and then at least annually once stable

• Annual diabetes reviews including assessment of blood pressure, renal function, lipid profile, and screening for diabetes complications

• Regular medication reviews to ensure that any ongoing prescriptions — including metformin — remain appropriate and necessary

Patients should be aware of the signs of hypoglycaemia (shakiness, sweating, confusion, palpitations) and hyperglycaemia (increased thirst, frequent urination, fatigue), and know when to seek medical advice. If blood glucose levels rise again after a period of remission, this should prompt a prompt GP review rather than self-adjustment of medication.

Not sure if this is normal? Chat with one of our pharmacists →

Red-flag symptoms requiring urgent medical attention include:

• Possible lactic acidosis (a rare but serious metformin-associated risk): unexplained fatigue, muscle pain, abdominal pain, difficulty breathing, or feeling cold. If these occur, stop metformin and seek urgent medical care

• Possible DKA (if on or recently restarted on an SGLT-2 inhibitor): nausea, vomiting, abdominal pain, or breathlessness — check ketones and seek urgent care even if blood glucose is not markedly elevated

Nutritional monitoring is an important part of long-term care after sleeve gastrectomy. BOMSS guidelines recommend lifelong micronutrient monitoring and supplementation following bariatric surgery, including regular checks of vitamin B12, iron, folate, vitamin D, and calcium, among others. Metformin itself is known to reduce vitamin B12 absorption over time, adding to the risk of deficiency in patients taking it long-term after surgery; B12 levels should therefore be monitored at least annually. Patients should follow the supplementation regimen recommended by their bariatric team and dietitian.

A collaborative approach between the patient, GP, bariatric team, and dietitian offers the best foundation for sustained health outcomes after gastric sleeve surgery. Patients should not adjust or stop any diabetes medicine without first seeking advice from their GP or specialist team.

Frequently Asked Questions